Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endonetics gets US okay for Gatekeeper trial:

This article was originally published in Clinica

Executive Summary

The US FDA has given Endonetics the go-ahead to begin a multicentre clinical trial of its endoscopic, reflux repair system in patients with gastroesophageal reflux disease (GERD). The Gatekeeper system will allow doctors to perform an outpatient, anti-reflux procedure in 60 minutes or less, claims its San Diego, California manufacturer. GERD, along with its major symptom, heartburn, is the most common disorder of the oesophagus, affecting around 75 million adults intermittently and 19 million on a daily basis in the US alone, says the company.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT071945

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel